1Chang M, Dahl ML, Tybring G, et al. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype[J]. Pharmacogenetics,1995,5(6):358-363.
2Kimura M, Ieiri I, Wada Y, et al. Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease, and length of therapy[J]. Br J Clin Pharmacol,1999,4(7):115-119.
3Hoskins JM,Shenfield GM,Gross AS, et al. Concordance between proguanil phenotype and CYP2C19 genotype in Chinese[J]. Eur J Clin Pharmaeol,2003,59(8-9):611-614.
4Funck-Brentano C, Becquemont L, Leneveu A, et al.Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in-vivo results from the in-vitro experiments [J]. Pharmacol Exp Ther,1997,280 (2) :730-738.
5Tanigawara Y, Kita T, Hirono M, et al. Identification of NAcetyltransferase 2 and CYP2C19 Genotypes for hair,buccal cell swabs, or fingernails compared with blood[J].Ther Drug Monit,2001,23(4):341-346.
8Ando T, Kato H,Sugimoto N,et al.A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences [J].Dig Dis Sci, 2005,50(9):1625-1631.
9Takada K,Arefayene M,Desta Z, et al.Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis[J].Arthritis Rheum,2004,50(7):2202-2210.
3[3]Jung F,Griffin KJ,Song W,et al.Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin metabolism to P4502C19[J].Biochemistry,1998,37(46):16270-16279.
4[4]Aynacioglu AS,Brockmoller J,Bauer S,et al.Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin[J].Br J Clin Pharmacol,1999,48(3):409-415.
5[5]de Morais SMF,Wilkinson GR,Blaisdell J,et al.The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans[J].J Biol Chem,1994,269(22):15419-15422.
6[6]Kunihiko I,Kazuyuki I,Hiroshi N,et al.Polymerase chain reaction-single-strand conformation polymorphism based determination of two major genetic defects responsible for a phenotypic polymorphism of cytochrome P450 (CYP) 2C19 in the Japanese population[J].Anal Biochem,2000,284(1):160-162.
7[7]Ninomiya H,Mamiya K,Matsuo S,et al.Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication[J].Ther Drug Monit,2000,22(2):230-232.
8Wrighton SA, Stevens JC, Becker GW, et al. Isolation and characterization of human liver cytochrome P450 2C19:correlation between 2C19 and S-mephenytoin 4'-hydroxylation[ J ]. Arch Biochem Biophys, 1993,306(1):240 - 5.
9Dojo M,Azuma T,Saito T,et al. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor ( omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan [J].Dig Liver Dis, 2001,3
10Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor,amoxicillin, and clarithromycin [ J ]. Clin Pharmacol Ther,2001,69(3) :158 -6
